- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00601406
Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer
Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy (RAPPER)
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This clinical trial is evaluating DNA mutations in predicting the effect of external-beam radiation therapy in patients with early breast cancer, localized prostate cancer, or gynecologic cancer.
연구 개요
상태
상세 설명
OBJECTIVES:
Primary
- To test the hypothesis that an association between common genetic variations, reported by single nucleotide polymorphisms (SNP) in relevant candidate genes, is associated with individual patient variability in normal tissue radiation response and toxicity.
Secondary
- To compare different clinical scoring systems for late normal tissue effects, specifically Late Effect of Normal Tissue Subjective Objective Management Analysis (LENT SOMA), Radiation Therapy Oncology Group (RTOG), quality of life, and in a subset common terminology criteria (CTC) version 3.
- To compare clinical scoring systems with analytical measures of normal tissue outcome in a minority of patients, using volume change in the breast measured by laser camera.
- To correlate family history information with SNP analysis to produce a polymorphism risk score (PRS) for family history.
- To compare a detailed 3D dose-volume analysis in a subset of patients with late effects and SNP results.
- To correlate actuarial analysis of late effects changes over time with PRS.
- To conduct PRS analyses against tumor control probability (TCP), using survival as a surrogate for TCP where necessary, and normal tissue complications vs tumor control probability.
OUTLINE: This is a multicenter study.
Patients are recruited from clinical trials in which their late normal tissue effects have been measured. Blood samples are collected from these patients for analysis of genetic variation by DNA extraction and single nucleotide polymorphism analysis. Sixty different genes, including those involved in cell cycle checkpoint control, DNA damage recognition and repair, induction of apoptosis, and cytokine production (including TGFβ pathways) are assessed.
연구 유형
등록 (예상)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
England
-
Brighton, England, 영국, BN2 5BE
- 모병
- Sussex Cancer Centre at Royal Sussex County Hospital
-
연락하다:
- Contact Person
- 전화번호: 44-12-7369-6955
-
Bristol, England, 영국, BS2 8ED
- 모병
- Bristol Haematology and Oncology Centre
-
연락하다:
- Contact Person
- 전화번호: 44-117-928-2415
-
Cambridge, England, 영국, CB2 2QQ
- 모병
- Addenbrooke's Hospital
-
연락하다:
- Contact Person
- 전화번호: 44-1223-336-800
-
Ipswich, England, 영국, IP4 5PD
- 모병
- Ipswich Hospital
-
연락하다:
- Contact Person
- 전화번호: 44-1473-704-177
-
Manchester, England, 영국, M20 4BX
- 모병
- Christie Hospital
-
연락하다:
- Contact Person
- 전화번호: 44-161-446-8275
-
Merseyside, England, 영국, CH63 4JY
- 모병
- Clatterbridge Centre for Oncology
-
연락하다:
- Contact Person
- 전화번호: 44-151-334-1155
-
Prescot, England, 영국, L35 5DR
- 모병
- Whiston Hospital
-
연락하다:
- Contact Person
- 전화번호: 44-151-334-1155
-
Sheffield, England, 영국, S1O 2SJ
- 모병
- Cancer Research Centre at Weston Park Hospital
-
연락하다:
- Contact Person
- 전화번호: 44-114-226-5000
-
Southport, England, 영국, PR8 6PN
- 모병
- Southport and Formby District General Hospital
-
연락하다:
- Contact Person
- 전화번호: 44-151-334-1155
-
Sutton, England, 영국, SM2 5PT
- 모병
- Royal Marsden - Surrey
-
연락하다:
- Contact Person
- 전화번호: 44-20-8661-3271
-
Warrington, England, 영국, WA5 1QG
- 모병
- Warrington Hospital NHS Trust
-
연락하다:
- Contact Person
- 전화번호: 44-151-334-1155
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
DISEASE CHARACTERISTICS:
Patients must have received curative external-beam radiotherapy within the context of a formal clinical study for any of the following:
- Early breast cancer after breast-conserving surgery
- Localized prostate cancer
- Gynecological cancer (may have also received brachytherapy)
- Venous blood samples must be available
Patients will be identified from the following clinical studies:
- Cambridge intensity-modulated radiotherapy breast randomized trial
- RT01 prostate radiotherapy randomized trial/other prostate trials
- Christie hospital breast, prostate, and gynecological cancer radiotherapy patients
- Must have minimum follow up with late normal tissue effect scoring for two years available
PATIENT CHARACTERISTICS:
- No other malignancy prior to treatment for the specified tumor types except basal cell or squamous cell carcinoma of the skin or in situ carcinoma
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 마스킹: 없음(오픈 라벨)
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
|---|
|
Correlation of association between common genetic variations, reported by single nucleotide polymorphisms (SNP) in relevant candidate genes, with individual patient variability in normal tissue radiation response and toxicity
|
2차 결과 측정
결과 측정 |
|---|
|
Comparison of different clinical scoring systems for late normal tissue effects
|
|
Comparison of clinical scoring systems with analytical measures of normal tissue outcome using volume change in the breast measured by laser camera
|
|
Correlation of family history information with SNP analysis to produce a polymorphism risk score (PRS)
|
|
Comparison of detailed 3D dose-volume analysis with late effects and SNP results
|
|
Correlation of actuarial analysis of late effects changes over time with PRS
|
|
PRS analyses against tumor control probability (TCP), using survival as a surrogate for TCP where necessary, and normal tissue complications vs tumor control probability
|
공동 작업자 및 조사자
수사관
- 연구 의자: Catherine West, The Christie NHS Foundation Trust
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
- 3기 전립선암
- 4기 난소 상피암
- 남성 유방암
- 2기 유방암
- IA기 유방암
- IB기 유방암
- 재발 원발성 복강암
- 1기 전립선암
- IIB기 전립선암
- IIA기 전립선암
- IIB기 자궁경부암
- 3기 자궁경부암
- IVA기 자궁경부암
- IB기 자궁경부암
- IIA기 자궁경부암
- IA기 난소 상피암
- IB기 난소 상피암
- IC기 난소 상피암
- IIA기 난소 상피암
- IIB기 난소 상피암
- IIC기 난소 상피암
- IIIA기 난소 상피암
- IIIB기 난소 상피암
- IIIC기 난소 상피암
- IA기 원발성 복강암
- IB기 원발성 복강암
- IC기 원발성 복강암
- IIA기 원발성 복강암
- IIB기 원발성 복강암
- IIC기 원발성 복강암
- IIIA 기 원발성 복강암
- IIIB기 원발성 복강암
- IIIC기 원발성 복강암
- IA기 나팔관암
- IB기 나팔관암
- IC기 나팔관암
- IIA기 나팔관암
- IIB기 나팔관암
- IIC기 나팔관암
- IIIA기 나팔관암
- IIIB기 나팔관암
- IIIC기 나팔관암
- 난소 육종
- IA기 자궁경부암
- IVB기 자궁경부암
- 난소 간질암
- IV기 난소 생식 세포 종양
- 3기 질암
- IVA기 질암
- IVB기 질암
- IIA기 난소 생식 세포 종양
- IIB기 난소 생식 세포 종양
- IIC기 난소 생식 세포 종양
- IIIA 기 난소 생식 세포 종양
- IIIB기 난소 생식 세포 종양
- IIIC기 난소 생식 세포 종양
- 1기 질암
- 2기 질암
- stage IA vulvar cancer
- stage IB vulvar cancer
- 2기 외음부암
- stage IIIC vulvar cancer
- stage IIIA vulvar cancer
- stage IIIB vulvar cancer
- IVB기 외음부암
- IA 기 난소 생식 세포 종양
- IB기 난소 생식 세포 종양
- IC기 난소 생식 세포 종양
- 2기 자궁내막 암종
- 4기 나팔관암
- 4기 원발성 복강암
- IA기 자궁내막 암종
- IB기 자궁내막 암종
- IIIA기 자궁내막 암종
- IIIB기 자궁내막 암종
- IIIC기 자궁내막 암종
- stage IVA endometrial carcinoma
- stage IVB endometrial carcinoma
- stage IA uterine sarcoma
- stage IB uterine sarcoma
- stage IC uterine sarcoma
- stage IIA uterine sarcoma
- stage IIB uterine sarcoma
- IIIA기 자궁 육종
- IIIB기 자궁 육종
- IIIC기 자궁 육종
- IVA기 자궁 육종
- IVB기 자궁 육종
추가 관련 MeSH 약관
기타 연구 ID 번호
- CDR0000581139
- CHNT-RAPPER
- EU-20798
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .